VARIPULSE + FARAWAVE Catheters for Atrial Fibrillation

(PERSIGMA RCT Trial)

This trial tests two catheters, VARIPULSE and FARAWAVE, to determine which is safer and more effective for treating persistent atrial fibrillation, a type of irregular, fast heartbeat lasting over a week. The goal is to identify the best option for individuals experiencing symptoms like a racing heart that doesn't stop on its own. Participants will undergo a procedure and receive monitoring for a year. This trial suits those diagnosed with persistent atrial fibrillation, who experience related symptoms, and have not received similar treatments before. As an unphased trial, it offers participants the chance to contribute to important research that could enhance treatment options for atrial fibrillation.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Previous studies have shown that the VARIPULSE PFA Catheter is quite safe for treating atrial fibrillation, a condition characterized by rapid and irregular heartbeats. Research found that only about 2.9% of patients experienced significant side effects, indicating a low risk of major issues. Another study reported an even lower rate of major side effects at just 0.6%, with no strokes occurring. These results suggest that the VARIPULSE catheter is generally well-tolerated.

The FARAWAVE PFA Catheter has also undergone safety testing. One study found that 5.1% of patients experienced serious side effects within 12 months, which is still considered a low rate. The FARAWAVE system is approved for use in other heart conditions, demonstrating that health authorities recognize its safety record.

Researchers are excited about the VARIPULSE and FARAWAVE catheters for treating atrial fibrillation because they use a novel approach called Pulsed Field Ablation (PFA). Unlike traditional ablation methods, which use heat or cold to destroy problematic heart tissue, PFA employs electrical pulses to precisely target and disrupt the heart cells causing the arrhythmia. This method is believed to be faster and potentially safer, reducing the risk of damage to surrounding healthy tissue. These advancements could lead to more effective treatments with fewer side effects for patients suffering from persistent atrial fibrillation.

This trial will compare the VARIPULSE PFA Catheter and the FARAWAVE PFA Catheter for treating atrial fibrillation. Research has shown that the VARIPULSE PFA Catheter is promising. One study reported that 87.7% of patients experienced no irregular heartbeat after one year, while another study found it to be 75% effective over 12 months. Similarly, the FARAWAVE PFA Catheter demonstrated strong results, with 73.4% of patients free from atrial fibrillation, atrial flutter, and atrial tachycardia after one year. Both treatments have proven effective, with solid evidence supporting their use for patients with ongoing atrial fibrillation.¹³⁴⁶⁷